



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/28

Date: 10th June 2026

To,

The Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: **Updates on incorporating a Limited Liability Company in United States of America as a wholly-owned Subsidiary of the Company**

Ref: **Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In continuation of the Company's disclosure dated 19th June 2025 (SPIL/CS/SE/2025-26/26), regarding approval of the Board to incorporate a limited liability company in United States of America as a wholly-owned subsidiary of the Company, pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that Sudarshan Industries Inc. ("Sudarshan USA") has been incorporated on Friday, 5th June 2026 as a wholly-owned subsidiary having service address in 8, The Green Ste R, Dover County, Kent - 19901.


The Company has subscribed to 1,00,00,000 shares of US \$0.00001 each of Sudarshan USA aggregating to US \$ 100 (approx. Rs.9,600/-) (100.00% of the paid-up share capital of Sudarshan USA).

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given in Annexure-A.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited


Hemal Mehta
Chairman & Managing Director



Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

Annexure A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given below:

| Sr. No. | Details to be Provided | Information |
|---------|--|--|
| 1 | Name of the target entity, details in brief such as size, etc. | Name: Sudarshan Industries Inc. (Sudarshan USA). To carry on the business to buy, sale, manufacture, process, import, export, promote, develop, wholesale and / or retail trade in all kinds and varieties of pharmaceuticals, antibiotics, drugs, medicines, biological, nutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, pharma intermediates, Active Pharmaceutical Ingredients, antibiotics, drugs, medicines, biologicals, nutraceuticals chemicals, chemical products, chemical compounds including speciality chemicals and other allied goods. |
| 2 | Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length' | No. The incorporation of a subsidiary does not fall within the related party transactions. |
| 3 | Industry to which the entity being acquired belongs. | To carry on the business to buy, sale, manufacture, process, import, export, promote, develop, wholesale and / or retail trade in all kinds and varieties of pharmaceuticals, antibiotics, drugs, medicines, biological, nutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, pharma intermediates, Active Pharmaceutical Ingredients, antibiotics, drugs, medicines, biologicals, nutraceuticals chemicals, chemical products, chemical compounds including speciality chemicals and other allied goods. |
| 4 | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | Sudarshan USA will enable the Company to enlarge its customer base in the USA. |





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • CIN : L51496MH2008PLC184997

| | | |
|----|---|---|
| 5 | Brief details of governmental or any regulatory approvals "required for the acquisition | Approval of the Reserve Bank of India under Foreign Exchange Management Act, 1999 Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time (approval under automatic route). |
| 6 | Indicative time period for completion of the acquisition | Not Applicable |
| 7 | Nature of Consideration whether Cash consideration or share swap and details of the same | The Company shall acquire the subscribed shares in cash and the same shall be remitted after obtaining necessary approval from the Reserve Bank of India. |
| 8 | Cost of acquisition or the price at which the shares are acquired. | Rs.9,600/- only or its equivalent in US Dollars (USD). |
| 9 | Percentage of shareholding control acquired and / or number of shares acquired | The Company has subscribed to 1,00,00,000 shares of US \$0.00001 each of Sudarshan USA aggregating to US\$ 100 (approx. Rs.9,600/-) (100.00% of the paid-up share capital of Sudarshan USA) |
| 10 | Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | <u>Brief background:</u> Sudarshan USA was incorporated as a wholly-owned subsidiary on Friday, 5 th June 2026 in Delaware, USA. Mr. Sachin Mehta, Joint Managing Director is appointed as the First Director of Sudarshan USA. |

For, Sudarshan Pharma Industries Limited


Hemal Mehta
Chairman & Managing Director

